ReviewFrontiers in microbiology2025
Respiratory microbiota, host immunity, respiratory viral infections and malignant tumors.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Attenuated efficacy of Streptococcus salivarius K12 against Mycoplasma pneumoniae infection in mice.BMC microbiology · 2026Article
- Functional characterization and safety evaluation of an airway commensalFrontiers in microbiology · 2026Article
- Development and validation of an immune-based nomogram model for predicting severe adenovirus pneumonia in hospitalized children.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the role of the respiratory tract microbiota in respiratory tract infections has attracted considerable attention. Respiratory microbiota have important effects on respiratory physiology, immune regulation, and the occurrence and development of various respiratory viral infectious diseases. The microbial composition in the different parts of the respiratory tract, such as the nose, oropharynx, and lower respiratory tract, varies. Under physiological conditions, the respiratory microbiota remains relatively stable; however, when this homeostatic balance is disrupted, respiratory microbiota imbalance occurs, increasing the risk of infection. An increasing number of studies have revealed the complex relationship between bacterial dysregulation and respiratory viral infections. Dysregulation of the respiratory tract microbiota plays an important role in both innate and adaptive immune responses. In this study, changes in respiratory microbes and their interactions with host immunity, respiratory viral infections and malignant tumors were reviewed. Future studies should further explore the interaction mechanism between respiratory microbiota and host immunity, develop new diagnostic and therapeutic strategies, and improve the current level of clinical treatment for respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.